Organisation paid for research Program year 2025 Source: CMS Open Payments

Cenexel CNS

Neither a doctor nor a teaching hospital

Research payments

$131,370

44 payments

Through program year 2025, Cenexel CNS is reported as receiving $131,370 in research payments, across 44 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $121,563 39
2024 Research $9,403 4
2023 Research $404 1

Breakdown

Who paid Research payments · program years 2023–2025
  1. Amgen Inc. $112,877 2 payments
  2. Boehringer Ingelheim International GmbH $9,852 37 payments
  3. Pfizer Inc. $5,523 2 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $2,034 1 payment
  5. AbbVie, Inc. $1,084 2 payments
Studies the money was for Research payments · program years 2023–2025
  1. A Phase 1, Open-label, Randomized, Parallel Group Study to Assess the Relative Bioavailability of Maridebart Cafraglutide (AMG 133) as Two Subcutaneous Presentations in Participants Living With Overweight or Obesity $63,256 1 payment
  2. A Phase 1, Open label, Randomized, Single Dose Crossover Study to Assess the Relative Bioavailability of Olpasiran (AMG 890) Autoinjector and Prefilled Syringe in Healthy Participants $49,621 1 payment
  3. A Phase Ib, multi-center, randomized, double-blind, parallel group, placebo-controlled trial to evaluate the effects on impulsivity, pharmacokinetics, safety, and tolerability of oral BI 1356225 in patients with opioid use disorder taking background buprenorphine treatment $8,686 37 payments
  4. A Phase 3 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of A Combined Modified Rna Vaccine Candidate Against Covid19 and Influenza in Healthy Individuals $5,523 2 payments
  5. PoCP Impulsivity in Opioid Use Disorder $3,199 1 payment
  6. A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder $840 1 payment
  7. A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia $244 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record